By Julie Steenhuysen CHICAGO (Reuters) -Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA signaled it might still win approval after Health Secretary Robert F.

Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the Food and Drug Administration

On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and Research (CBER)—who resigned in March—warned that the mass downsizing at the agency could hamstring the regulator’s ability to review drugs beginning in 2026 or 2027.